British pharmaceutical giant GSK announces end of operation in Nigeria

British multinational drugmaker and biotechnology corporation GlaxoSmithKline Plc (GSK) reported Thursday it is drawing the blinds on its Nigerian subsidiary soon after a “strategic intent” to take into account other favourable organization possibilities.

GSK’s operations in Nigeria will no lengthier require commercialising its prescription drugs and vaccines, meaning its functions in the place now entail the distribution of its pharmaceutical merchandise through a third social gathering only.

“The Haleon Team has also separately knowledgeable the Board of its intent to terminate its distribution agreement in the coming months and to appoint a 3rd-party distributor in Nigeria for the supply of its buyer healthcare items,” the enterprise said in a note to the Nigerian Trade.
The decision cuts GSK’s ties of additional than fifty percent a century with Africa’s greatest financial state, the place it commenced business in 1972 through its precursor, Beecham Restricted.

That partnership has birthed a wide array of major-of-brain items from purchaser brand names like Ribena, Lucozade Macleans and Sensodyne to preferred medications like Panadol and Andrews Liver Salt, which several Nigerians have developed an affinity for.

“Today we are briefing our workforce whom we will address quite, respectfully and with treatment, conference all applicable legal and session needs,” the enterprise confident.

Browse ALSO: Weak gross sales stretch Unilever’s decline into second calendar year

GSK explained it is keeping talks with advisors who will advise shareholders of the following class of action and will operate out a brief income distribution and return of cash to shareholders, excluding GSK United kingdom, if the Securities and Trade Fee sanctions the program.

The release fell on the very same day GSK Nigeria printed its fifty percent-calendar year 2023 financials demonstrating a plunge by pretty much 50 percent in revenue to N7.8 billion from N14.8 billion a calendar year ago.

This March, Unilever, one more British shopper product or service powerhouse Unilever declared an end to the output of its homecare and pores and skin-cleaning products and solutions, notably Lux, Daylight and Omo, stating “These types are margin dilutive and the exit is element of the company’s intention to make its operation in Nigeria aggressive and worthwhile.”